Moderna announces positive Phase 3 efficacy data for next generation COVID-19 vaccine
Higher efficacy was observed in mRNA-1283 compared to Spikevax in adults 18 years of age and older
Higher efficacy was observed in mRNA-1283 compared to Spikevax in adults 18 years of age and older
The Indian pharmaceutical industry is projected to reach US$ 130 billion by 2030
Dr. Reddy’s gets exclusive commercialization rights in the United States (U.S.) as well as semi-exclusive rights in Europe and United Kingdom (UK)
The acquisition is immediately accretive and creates a compelling, single-stop, multi-continent partner for biopharma companies
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Investing considerably in production capacity for medical device packaging at its Rohrdorf and Halle sites in Germany
Recommendation based on CAPItello-291 results which showed the Truqap combination reduced the risk of disease progression or death by 50%
Biocon will undertake the development, manufacturing and supply of the drug product, and Biomm will be responsible for obtaining regulatory approval and commercialization in the Brazilian market
SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva
Subscribe To Our Newsletter & Stay Updated